AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

StemExpress Welcomes Dr. Victoria Hines as Vice President of Clinical

February 6, 2020 GMT

FOLSOM, Calif.--(BUSINESS WIRE)--Feb 6, 2020--

StemExpress announced that Dr. Victoria Hines has been appointed Vice President of Clinical and will direct the company as they expand their offerings to include clinical grade products. Hines will lead global clinical operations, strategy and execution for StemExpress.

The increasing demand for cell and gene therapies to treat various diseases such as cancer, is expected to grow at a phenomenal rate. Companies are significantly investing in clinical trials as many innovative cell and gene therapy products have entered the early stage of clinical development.

“This space is absolutely transformative for healthcare,” said Hines. “I’m excited to be a part of this ecosystem to bring cell therapies to patients around the world.”

Hines has a Ph.D. in Cell and Molecular Biology from the University of Chicago, a BA in Biology from Carleton College and has worked in the biotech and pharmaceutical industries for more than 30 years. She has extensive experience with late stage clinical trials, regulatory affairs, business strategy and program leadership.

“Vicky’s vast experience in research and development, combined with her knowledge of commercial and clinical programs will position StemExpress as a leader to meet the growing demand for clinical grade applications and products,” said Cate Dyer, StemExpress Founder and CEO.

Hines joins the StemExpress Executive Leadership team at their headquarters in Folsom, California.

About StemExpress, LLC

StemExpress is a leading provider of human bone marrow, cord blood, peripheral blood, mobilized peripheral blood, maternal blood, diseased blood, and human primary cells. With six collection centers around the U.S., StemExpress has a reliable and streamlined process starting with donor recruitment to shipping the final product guaranteeing every sample has the highest purity, viability, and quality.

For more information, please visit https://www.stemexpress.com/clinical-grade-products/ or call 530-626-7000.

View source version on businesswire.com:https://www.businesswire.com/news/home/20200206005164/en/

CONTACT: Katherine Elorduy

Cell: 916-217-9727

kelorduy@stemexpress.com

KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA

INDUSTRY KEYWORD: ONCOLOGY HEALTH STEM CELLS GENETICS CLINICAL TRIALS PHARMACEUTICAL BIOTECHNOLOGY

SOURCE: StemExpress, LLC

Copyright Business Wire 2020.

PUB: 02/06/2020 01:00 PM/DISC: 02/06/2020 01:01 PM

http://www.businesswire.com/news/home/20200206005164/en